The Role of Apolipoprotein E in Alzheimer's Disease

The epsilon4 allele of apolipoprotein E (APOE) is the major genetic risk factor for Alzheimer's disease (AD). Although there have been numerous studies attempting to elucidate the underlying mechanism for this increased risk, how apoE4 influences AD onset and progression has yet to be proven. However, prevailing evidence suggests that the differential effects of apoE isoforms on Abeta aggregation and clearance play the major role in AD pathogenesis. Other potential mechanisms, such as the differential modulation of neurotoxicity and tau phosphorylation by apoE isoforms as well as its role in synaptic plasticity and neuroinflammation, have not been ruled out. Inconsistent results among studies have made it difficult to define whether the APOE epsilon4 allele represents a gain of toxic function, a loss of neuroprotective function, or both. Therapeutic strategies based on apoE propose to reduce the toxic effects of apoE4 or to restore the physiological, protective functions of apoE.

[1]  S. Thibodeau,et al.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.

[2]  D. Holtzman,et al.  The Low Density Lipoprotein Receptor Regulates the Level of Central Nervous System Human and Murine Apolipoprotein E but Does Not Modify Amyloid Plaque Pathology in PDAPP Mice* , 2005, Journal of Biological Chemistry.

[3]  J. Gilbert,et al.  Defective neuronal sprouting by human apolipoprotein E4 is a gain‐of‐negative function , 2002, Journal of neuroscience research.

[4]  R. Mahley,et al.  Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. , 1994, Science.

[5]  Lars-Olof Wahlund,et al.  Structural and Quantitative Comparison of Cerebrospinal Fluid Glycoproteins in Alzheimer’s Disease Patients and Healthy Individuals , 2008, Neurochemical Research.

[6]  Jordan J. N. Tang,et al.  Apolipoprotein Receptor 2 and X11α/β Mediate Apolipoprotein E-Induced Endocytosis of Amyloid-β Precursor Protein and β-Secretase, Leading to Amyloid-β Production , 2007, The Journal of Neuroscience.

[7]  Inder M Verma,et al.  Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Squazzo,et al.  Evidence that production and release of amyloid beta-protein involves the endocytic pathway. , 1994, The Journal of biological chemistry.

[9]  P. Wolf,et al.  Association of APOE genotype with carotid atherosclerosis in men and women: the Framingham Heart Study. , 2004, Journal of lipid research.

[10]  A. Takeshita,et al.  Altered cholesterol metabolism in human apolipoprotein E4 knock-in mice. , 2000, Human molecular genetics.

[11]  Bruce J Aronow,et al.  ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition Evidence that ApoE Regulates Extracellular Aβ Metabolism In Vivo , 2004, Neuron.

[12]  H. Bock,et al.  Lipoprotein receptors in the nervous system. , 2002, Annual review of biochemistry.

[13]  Frank W Pfrieger,et al.  New roles for astrocytes: Regulation of CNS synaptogenesis , 2003, Trends in Neurosciences.

[14]  P. Lansbury,et al.  Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Sulkava,et al.  APOE ε4 does not predict mortality, cognitive decline, or dementia in the oldest old , 2000, Neurology.

[16]  M. Hayden,et al.  The Absence of ABCA1 Decreases Soluble ApoE Levels but Does Not Diminish Amyloid Deposition in Two Murine Models of Alzheimer Disease* , 2005, Journal of Biological Chemistry.

[17]  Edu,et al.  Molecular Neurodegeneration Apolipoprotein E Levels in Cerebrospinal Fluid and the Effects of Abca1 Polymorphisms , 2022 .

[18]  A D Roses,et al.  Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Katie Hamm,et al.  apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. , 2008, The Journal of clinical investigation.

[20]  S. Paul,et al.  Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[21]  P A Wolf,et al.  Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. , 1994, JAMA.

[22]  R. Mahley,et al.  Stable Expression and Secretion of Apolipoproteins E3 and E4 in Mouse Neuroblastoma Cells Produces Differential Effects on Neurite Outgrowth (*) , 1995, The Journal of Biological Chemistry.

[23]  R. J. Kelleher,et al.  The presenilin hypothesis of Alzheimer's disease: Evidence for a loss-of-function pathogenic mechanism , 2007, Proceedings of the National Academy of Sciences.

[24]  G. Alexander,et al.  Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[25]  L. Fratiglioni,et al.  Role of genes and environments for explaining Alzheimer disease. , 2006, Archives of general psychiatry.

[26]  Irwin D Kuntz,et al.  Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  G. Siest,et al.  Apolipoprotein E (apoE) uptake and distribution in mammalian cell lines is dependent upon source of apoE and can be monitored in living cells , 2003, Neuroscience Letters.

[28]  B T Hyman,et al.  Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease , 1996, Annals of neurology.

[29]  Bruce J Aronow,et al.  Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Piette,et al.  Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1 , 1999, Nature Genetics.

[31]  F. Sacks,et al.  Apolipoprotein-mediated pathways of lipid antigen presentation , 2005, Nature.

[32]  A. Fagan,et al.  Human and Murine ApoE Markedly Alters Aβ Metabolism before and after Plaque Formation in a Mouse Model of Alzheimer's Disease , 2002, Neurobiology of Disease.

[33]  C. Wernstedt,et al.  Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brain , 1995, Neuron.

[34]  C. Kelche,et al.  Human apoE targeted replacement mouse lines: h-apoE4 and h-apoE3 mice differ on spatial memory performance and avoidance behavior , 2005, Behavioural Brain Research.

[35]  David Walker,et al.  Profile and Regulation of Apolipoprotein E (ApoE) Expression in the CNS in Mice with Targeting of Green Fluorescent Protein Gene to the ApoE Locus , 2006, The Journal of Neuroscience.

[36]  R. Martins,et al.  Apolipoprotein E promotes the binding and uptake of β-amyloid into Chinese hamster ovary cells in an isoform-specific manner , 1999, Neuroscience.

[37]  T. Bliss,et al.  Behavioural, physiological and morphological analysis of a line of apolipoprotein E knockout mouse , 1998, Neuroscience.

[38]  A. Fagan,et al.  Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. , 1999, The Journal of clinical investigation.

[39]  H. Soininen,et al.  Alzheimer pathology of patients carrying apolipoprotein E epsilon 4 allele. , 1995, Neurobiology of aging.

[40]  E B Larson,et al.  Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease. , 1998, Neurology.

[41]  T. Lehtimäki,et al.  Apolipoprotein E (apoE) levels in brains from Alzheimer disease patients and controls , 1996, Brain Research.

[42]  G. Cole,et al.  Influence of lipoproteins on microglial degradation of Alzheimer's amyloid beta‐protein , 2000, Microscopy research and technique.

[43]  A. D. de Craen,et al.  ApoE Plasma Levels and Risk of Cardiovascular Mortality in Old Age , 2006, PLoS medicine.

[44]  T. V. van Berkel,et al.  Apolipoprotein E Is Resistant to Intracellular Degradation in Vitro and in Vivo , 2000, The Journal of Biological Chemistry.

[45]  G. Schellenberg,et al.  Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. , 2008, Journal of Alzheimer's disease : JAD.

[46]  A. Kontush.  Alzheimer's amyloid-beta as a preventive antioxidant for brain lipoproteins. , 2001, Cellular and molecular neurobiology.

[47]  M. Mattson,et al.  Truncated Apolipoprotein E (ApoE) Causes Increased Intracellular Calcium and May Mediate ApoE Neurotoxicity , 1999, The Journal of Neuroscience.

[48]  H. Soininen,et al.  Alzheimer pathology of patients carrying apoliprotein E ϵ4 allele , 1995, Neurobiology of Aging.

[49]  A. Sporbert,et al.  SorLA/LR11 Regulates Processing of Amyloid Precursor Protein via Interaction with Adaptors GGA and PACS-1* , 2007, Journal of Biological Chemistry.

[50]  L. Mucke,et al.  Modulation of Alzheimer-Like Synaptic and Cholinergic Deficits in Transgenic Mice by Human Apolipoprotein E Depends on Isoform , Aging, and Overexpression of Amyloid β Peptides But Not on Plaque Formation , 2002, The Journal of Neuroscience.

[51]  A. Levey,et al.  Loss of LR11/SORLA Enhances Early Pathology in a Mouse Model of Amyloidosis: Evidence for a Proximal Role in Alzheimer's Disease , 2008, The Journal of Neuroscience.

[52]  L. Thal,et al.  Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease , 2004, Neurology.

[53]  D. Michaelson,et al.  A nontransgenic mouse model shows inducible amyloid-β (Aβ) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade , 2004 .

[54]  W. Strittmatter,et al.  APOE genotype-specific differences in human and mouse macrophage nitric oxide production , 2004, Journal of Neuroimmunology.

[55]  S. Paul,et al.  Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition , 1997, Nature Genetics.

[56]  D. Blacker,et al.  Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database , 2007, Nature Genetics.

[57]  C. Bouras,et al.  Clusterin expression during fetal and postnatal CNS development in mouse , 2008, Neuroscience.

[58]  T. Lehtimäki,et al.  Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease , 2004, Human Genetics.

[59]  Holly Soares,et al.  Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. , 2004, Biological psychiatry.

[60]  L. Grinberg,et al.  Human apolipoprotein A-I binds amyloid-beta and prevents Abeta-induced neurotoxicity. , 2009, The international journal of biochemistry & cell biology.

[61]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[62]  Y. Zhi.  Apolipoprotein E Alleles, Dyslipidemia,and Coronary Heart Disease , 2001 .

[63]  J. Herz,et al.  Reelin, lipoprotein receptors and synaptic plasticity , 2006, Nature Reviews Neuroscience.

[64]  L. Mucke,et al.  Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[65]  D. Selkoe.  Clearing the Brain's Amyloid Cobwebs , 2001, Neuron.

[66]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[67]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[68]  G. Getz,et al.  Apolipoprotein E and apolipoprotein E receptors modulate Aβ-induced glial neuroinflammatory responses , 2001, Neurochemistry International.

[69]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[70]  D. Holtzman,et al.  Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. , 2008, The Journal of clinical investigation.

[71]  T. Südhof,et al.  Binding of F-spondin to amyloid-beta precursor protein: a candidate amyloid-beta precursor protein ligand that modulates amyloid-beta precursor protein cleavage. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[72]  J. Poirier,et al.  Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures. , 1999, Brain research. Molecular brain research.

[73]  E. Masliah,et al.  Neurodegeneration and cognitive impairment in apoE-deficient mice is ameliorated by infusion of recombinant apoE , 1997, Brain Research.

[74]  D. Holtzman,et al.  Neuroinflammation and Alzheimer’s disease: critical roles for cytokine/Aβ-induced glial activation, NF-κB, and apolipoprotein E , 2000, Neurobiology of Aging.

[75]  Gregory J. Brewer,et al.  Apolipoprotein E4 inhibits, and apolipoprotein E3 promotes neurite outgrowth in cultured adult mouse cortical neurons through the low-density lipoprotein receptor-related protein , 2002, Brain Research.

[76]  A. Fagan,et al.  Lipoproteins in the Central Nervous System , 2000, Annals of the New York Academy of Sciences.

[77]  A. Fagan,et al.  Evidence for Normal Aging of the Septo-Hippocampal Cholinergic System in apoE (−/−) Mice but Impaired Clearance of Axonal Degeneration Products Following Injury , 1998, Experimental Neurology.

[78]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[79]  D. Selkoe,et al.  Co-expression of β-amyloid precursor protein (βAPP) and apolipoprotein E in cell culture: analysis of βAPP processing , 1995, Neurobiology of Disease.

[80]  M. Brown,et al.  A receptor-mediated pathway for cholesterol homeostasis. , 1986, Science.

[81]  Y. Ihara,et al.  Apolipoprotein E genotype, Alzheimer's pathologies and related gene expression in the aged population. , 1995, Brain research. Molecular brain research.

[82]  K Kontula,et al.  Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. , 1995, The New England journal of medicine.

[83]  D. Holtzman,et al.  ApoE Promotes the Proteolytic Degradation of Aβ , 2008, Neuron.

[84]  A. Fagan,et al.  P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. , 2005, The Journal of clinical investigation.

[85]  M. Staufenbiel,et al.  Lack of ABCA1 Considerably Decreases Brain ApoE Level and Increases Amyloid Deposition in APP23 Mice* , 2005, Journal of Biological Chemistry.

[86]  Carol A. Colton,et al.  APOE genotype-specific differences in the innate immune response , 2009, Neurobiology of Aging.

[87]  R. Tanzi,et al.  Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective , 2005, Cell.

[88]  G. Getz,et al.  Apolipoprotein E Receptors Mediate the Effects of β-Amyloid on Astrocyte Cultures* , 2000, The Journal of Biological Chemistry.

[89]  G. Bu,et al.  Modulation of β-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family , 2006, Molecular Neurodegeneration.

[90]  M. Yamada,et al.  Apolipoprotein E and the neuropathology of dementia. , 1996, The New England journal of medicine.

[91]  B. Hyman,et al.  Brain Expression of Apolipoproteins E, J, and A‐I in Alzheimer's Disease , 1996, Journal of neurochemistry.

[92]  D. Fredrickson,et al.  Tangier disease (familial high density lipoprotein deficiency). Clinical and genetic features in two adults. , 1965, The American journal of medicine.

[93]  G. Alexander,et al.  Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[94]  A. Roses,et al.  Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. , 1994, The Journal of clinical investigation.

[95]  J. Ma,et al.  Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. , 1994, Nature.

[96]  P. S. St George-Hyslop,et al.  Loss of γ-Secretase Function Impairs Endocytosis of Lipoprotein Particles and Membrane Cholesterol Homeostasis , 2008, The Journal of Neuroscience.

[97]  R. Koeppe,et al.  A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[98]  J. Gilbert,et al.  Sialylated Human Apolipoprotein E (apoEs) Is Preferentially Associated with Neuron-Enriched Cultures from APOE Transgenic Mice , 1999, Neurobiology of Disease.

[99]  T. Wisniewski,et al.  The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. , 1993, The Biochemical journal.

[100]  D. Dickson,et al.  Abeta40 inhibits amyloid deposition in vivo. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[101]  J. Hardy,et al.  Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice , 2005, Neuron.

[102]  R. Sulkava,et al.  APOE epsilon4 does not predict mortality, cognitive decline, or dementia in the oldest old. , 2000, Neurology.

[103]  L. Mucke,et al.  Alzheimer's disease: Apolipoprotein E and cognitive performance , 2000, Nature.

[104]  R. Wetzel,et al.  Seeding of A beta fibril formation is inhibited by all three isotypes of apolipoprotein E. , 1996, Biochemistry.

[105]  S. Barger,et al.  Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E , 1997, Nature.

[106]  R. Veerhuis,et al.  Binding and uptake of Aβ1‐42 by primary human astrocytes in vitro , 2009, Glia.

[107]  A. Fagan,et al.  ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis. , 2004, The American journal of pathology.

[108]  D. Dickson,et al.  Aβ40 Inhibits Amyloid Deposition In Vivo , 2007, The Journal of Neuroscience.

[109]  B. Zlokovic,et al.  Blood-brain barrier transport of circulating Alzheimer's amyloid beta. , 1993, Biochemical and biophysical research communications.

[110]  S. Corkin,et al.  Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease , 1996, Neurology.

[111]  T. Ohm,et al.  Apolipoprotein E polymorphism and dendritic shape in hippocampal interneurons , 2007, Neurobiology of Aging.

[112]  A. Vaughan,et al.  The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. , 1999, The Journal of clinical investigation.

[113]  L. Thal,et al.  The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant , 1996, Neurology.

[114]  L. Bernier,et al.  Deficiency of ABCA1 Impairs Apolipoprotein E Metabolism in Brain* , 2004, Journal of Biological Chemistry.

[115]  A D Roses,et al.  Apolipoprotein E alleles as risk factors in Alzheimer's disease. , 1996, Annual review of medicine.

[116]  Guojun Bu,et al.  Endocytosis Is Required for Synaptic Activity-Dependent Release of Amyloid-β In Vivo , 2008, Neuron.

[117]  D. Holtzman,et al.  The Low‐Density Lipoprotein Receptor‐Related Protein, a Multifunctional Apolipoprotein E Receptor, Modulates Hippocampal Neurite Development , 1997, Journal of neurochemistry.

[118]  A. Levey,et al.  Loss of apolipoprotein E receptor LR11 in Alzheimer disease. , 2004, Archives of neurology.

[119]  A. Fagan,et al.  Apolipoprotein E-containing High Density Lipoprotein Promotes Neurite Outgrowth and Is a Ligand for the Low Density Lipoprotein Receptor-related Protein* , 1996, The Journal of Biological Chemistry.

[120]  R. Mahley,et al.  Increased tau Phosphorylation in Apolipoprotein E4 Transgenic Mice Is Associated with Activation of Extracellular Signal-regulated Kinase , 2004, Journal of Biological Chemistry.

[121]  Lars Bäckman,et al.  Apolipoprotein E and cognitive performance: a meta-analysis. , 2004, Psychology and aging.

[122]  B. Hyman,et al.  APOE ε3/ε4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer’s disease diagnosis , 2003, Experimental Neurology.

[123]  T. Langmann,et al.  The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease , 1999, Nature Genetics.

[124]  C. Haass,et al.  Intramembrane proteolysis by presenilins , 2000, Nature Reviews Molecular Cell Biology.

[125]  Xianlin Han,et al.  ABCA1 Is Required for Normal Central Nervous System ApoE Levels and for Lipidation of Astrocyte-secreted apoE* , 2004, Journal of Biological Chemistry.

[126]  R. Ravid,et al.  Reduced Levels of Cholesterol, Phospholipids, and Fatty Acids in Cerebrospinal Fluid of Alzheimer Disease Patients Are Not Related to Apolipoprotein E4 , 1998, Alzheimer disease and associated disorders.

[127]  B. Chromy,et al.  Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. , 1998, Brain research.

[128]  T. Terasaki,et al.  Cerebral clearance of human amyloid‐β peptide (1–40) across the blood–brain barrier is reduced by self‐aggregation and formation of low‐density lipoprotein receptor‐related protein‐1 ligand complexes , 2007, Journal of neurochemistry.

[129]  A. Roses,et al.  Impaired Neuronal Plasticity in Transgenic Mice Expressing Human Apolipoprotein E4 Compared to E3 in a Model of Entorhinal Cortex Lesion , 2001, Neurobiology of Disease.

[130]  P. S. St George-Hyslop,et al.  Abeta1-40 but not Abeta1-42 levels in cortex correlate with apolipoprotein E epsilon4 allele dosage in sporadic Alzheimer's disease. , 1997, Brain research.

[131]  B. Hyman,et al.  Apolipoprotein E affects the amount, form, and anatomical distribution of amyloid β-peptide deposition in homozygous APPV717F transgenic mice , 2000, Acta Neuropathologica.

[132]  E. Boerwinkle,et al.  Sequence diversity and large-scale typing of SNPs in the human apolipoprotein E gene. , 2000, Genome research.

[133]  Charles Ramassamy,et al.  Apolipoprotein E and β-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent , 1999, Brain Research.

[134]  T. Asada,et al.  ApoE epsilon 4 allele and cognitive decline in patients with Alzheimer's disease , 1996, Neurology.

[135]  M. Gearing,et al.  Abeta-peptide length and apolipoprotein E genotype in Alzheimer's disease. , 1996, Annals of Neurology.

[136]  S. Leurgans,et al.  Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment. , 2011, Archives of neurology.

[137]  G. Getz,et al.  Effect of Apolipoprotein E on Neurite Outgrowth and β‐Amyloid‐Induced Toxicity in Developing Rat Primary Hippocampal Cultures , 1997, Journal of neurochemistry.

[138]  Kewei Chen,et al.  Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[139]  Sung Hwan Yun,et al.  ApoE isoform affects LTP in human targeted replacement mice , 2004, Neuroreport.

[140]  K. Blennow,et al.  The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[141]  D. Holtzman,et al.  Transport Pathways for Clearance of Human Alzheimer's Amyloid β-Peptide and Apolipoproteins E and J in the Mouse Central Nervous System , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[142]  W. März,et al.  Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation , 1995, Neuroscience.

[143]  T. Lanz,et al.  Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype , 2003, Neurobiology of Disease.

[144]  H. Braak,et al.  High Frequency of Apolipoprotein E ϵ4 Allele in Young Individuals with Very Mild Alzheimer's Disease-Related Neurofibrillary Changes , 1998, Experimental Neurology.

[145]  D. C. Harris,et al.  Multiple pathways of apolipoprotein E signaling in primary neurons , 2005, Journal of neurochemistry.

[146]  H. Brewer,et al.  Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments , 1994, Nature.

[147]  Piero Antuono,et al.  Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors , 2008, The Lancet Neurology.

[148]  D. Holtzman,et al.  Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[149]  Yaakov Stern,et al.  The APOE-∊4 Allele and the Risk of Alzheimer Disease Among African Americans, Whites, and Hispanics , 1998 .

[150]  B. Winblad,et al.  Effects of apolipoprotein E (apoE) isoforms, β-amyloid (Aβ) and apoE/Aβ complexes on Protein Kinase C-α (PKC-α) translocation and amyloid precursor protein (APP) processing in human SH-SY5Y neuroblastoma cells and fibroblasts , 2001, Neurochemistry International.

[151]  H. Brewer,et al.  Alzheimer Aβ neurotoxicity: Promotion by antichymotrypsin, ApoE4; inhibition by Aβ-related peptides , 1996, Neurobiology of Aging.

[152]  A. M. Saunders,et al.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease , 1994, Nature Genetics.

[153]  T Vogel,et al.  Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. , 1994, The American journal of pathology.

[154]  Thomas Wisniewski,et al.  Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid , 1992, Neuroscience Letters.

[155]  N. Inestrosa,et al.  ApoER2 expression increases Aβ production while decreasing Amyloid Precursor Protein (APP) endocytosis: Possible role in the partitioning of APP into lipid rafts and in the regulation of γ-secretase activity , 2007, Molecular Neurodegeneration.

[156]  D. Berlau,et al.  APOE ε2 is associated with intact cognition but increased Alzheimer pathology in the oldest old , 2009, Neurology.

[157]  Shu Wang,et al.  [Expression of apolipoprotein E in Alzheimer's disease and its significance]. , 2005, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[158]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[159]  B. Zlokovic.  The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders , 2008, Neuron.

[160]  G. Siest,et al.  Conformation of apolipoprotein E both in free and in lipid-bound form may determine the avidity of triglyceride-rich lipoproteins to the LDL receptor: structural and kinetic study. , 2000, Biochimica et biophysica acta.

[161]  D. Holtzman,et al.  Behavioral Phenotyping of GFAP-ApoE3 and -ApoE4 Transgenic Mice: ApoE4 Mice Show Profound Working Memory Impairments in the Absence of Alzheimer's-like Neuropathology , 2001, Experimental Neurology.

[162]  M. Stewart,et al.  Synaptic loss is accompanied by an increase in synaptic area in the dentate gyrus of aged human Apolipoprotein E4 transgenic mice , 2000, Neuroscience.

[163]  Relative efficacies of amyloid beta peptide (A beta) binding proteins in A beta aggregation. , 1996, Journal of neuroscience research.

[164]  M. Nieminen,et al.  Apolipoprotein E polymorphism is associated with both carotid and coronary atherosclerosis in patients with coronary artery disease. , 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[165]  B. Hyman,et al.  APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis. , 2003, Experimental neurology.

[166]  N. Maeda,et al.  Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. , 1998, The Journal of clinical investigation.

[167]  D. Laskowitz,et al.  Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response , 2001, Journal of Neuroimmunology.

[168]  C. Kelche,et al.  Middle-aged human apoE4 targeted-replacement mice show retention deficits on a wide range of spatial memory tasks , 2008, Behavioural Brain Research.

[169]  A Rostagno,et al.  Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. , 2000, The Biochemical journal.

[170]  C. Morris,et al.  Effect of apolipoprotein E genotype on Alzheimer's disease neuropathology in a cohort of elderly Norwegians , 1995, Neuroscience Letters.

[171]  R. Demattos,et al.  Apolipoprotein E dose-dependent modulation of β-amyloid deposition in a transgenic mouse model of Alzheimer’s disease , 2007, Journal of Molecular Neuroscience.

[172]  M. Pericak-Vance,et al.  Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[173]  M. Sugano,et al.  Isoform-specific effect of apolipoprotein E on endocytosis of beta-amyloid in cultures of neuroblastoma cells. , 2002, Annals of clinical and laboratory science.

[174]  N. Maeda,et al.  Targeted Replacement of the Mouse Apolipoprotein E Gene with the Common Human APOE3 Allele Enhances Diet-induced Hypercholesterolemia and Atherosclerosis* , 1997, The Journal of Biological Chemistry.

[175]  A. Fagan,et al.  Glial Fibrillary Acidic Protein–Apolipoprotein E (apoE) Transgenic Mice: Astrocyte-Specific Expression and Differing Biological Effects of Astrocyte-Secreted apoE3 and apoE4 Lipoproteins , 1998, The Journal of Neuroscience.

[176]  T. Südhof,et al.  Binding of F-spondin to amyloid-β precursor protein: A candidate amyloid-β precursor protein ligand that modulates amyloid-β precursor protein cleavage , 2004 .

[177]  Rachelle S. Doody,et al.  Individual Growth Curve Analysis of APOE ε4–Associated Cognitive Decline in Alzheimer Disease , 2005 .

[178]  A. Nakagawara,et al.  Effect of apolipoprotein AII on the interaction of apolipoprotein E with β‐amyloid: Some apo(E–AII) complexes inhibit the internalization of β‐amyloid in cultures of neuroblastoma cells , 2000, Journal of neuroscience research.

[179]  Meir J Stampfer,et al.  Meta-Analysis: Apolipoprotein E Genotypes and Risk for Coronary Heart Disease , 2004, Annals of Internal Medicine.

[180]  B. Winblad,et al.  Effects of apolipoprotein E (apoE) isoforms, beta-amyloid (Abeta) and apoE/Abeta complexes on protein kinase C-alpha (PKC-alpha) translocation and amyloid precursor protein (APP) processing in human SH-SY5Y neuroblastoma cells and fibroblasts. , 2001, Neurochemistry international.

[181]  C. Abraham,et al.  Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease. , 1997, Biochemistry.

[182]  A. Fagan,et al.  Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[183]  K. Marder,et al.  Contributions The APOE-e 4 Allele and the Risk of Alzheimer Disease Among African Americans , Whites , and Hispanics , 2001 .

[184]  R. Martins,et al.  Characterization of the Binding of Amyloid‐β Peptide to Cell Culture‐Derived Native Apolipoprotein E2, E3, and E4 Isoforms and to Isoforms from Human Plasma , 1997, Journal of neurochemistry.

[185]  J. Gilbert,et al.  Human Apolipoprotein E Isoform‐Specific Differences in Neuronal Sprouting in Organotypic Hippocampal Culture , 1999, Journal of neurochemistry.

[186]  L. Muglia,et al.  Amyloid Precursor Protein Regulates Brain Apolipoprotein E and Cholesterol Metabolism through Lipoprotein Receptor LRP1 , 2007, Neuron.

[187]  N. Tommerup,et al.  Molecular Characterization of a Novel Human Hybrid-type Receptor That Binds the α2-Macroglobulin Receptor-associated Protein* , 1996, The Journal of Biological Chemistry.

[188]  A. Smith,et al.  Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease , 1995, Neuroscience.

[189]  M. Pangalos,et al.  Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels , 2008, The Journal of Neuroscience.

[190]  T. Arendt,et al.  Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. , 1997, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[191]  S. Leurgans,et al.  Neuronal LR11/sorLA expression is reduced in mild cognitive impairment , 2007, Annals of neurology.

[192]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[193]  R. Mahley,et al.  Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[194]  J. Taylor,et al.  Glycosylation of human apolipoprotein E. The carbohydrate attachment site is threonine 194. , 1989, The Journal of biological chemistry.

[195]  J. Poirier,et al.  ApoE associated with lipid has a reduced capacity to inhibit β‐amyloid fibril formation , 1998, Neuroreport.

[196]  K. Blennow,et al.  Apolipoprotein E in cerebrospinal fluid from patients with Alzheimer's disease and other forms of dementia is reduced but without any correlation to the apoE4 isoform. , 1996, Dementia.

[197]  J. Gilbert,et al.  Differential neurotrophic effects of apolipoprotein E in aged transgenic mice , 1999, Neuroscience Letters.

[198]  S. Paul,et al.  Apolipoprotein E alters the processing of the β-amyloid precursor protein in APPV717F transgenic mice , 2002, Brain Research.

[199]  Johnm . Taylor,et al.  Two Distal Downstream Enhancers Direct Expression of the Human Apolipoprotein E Gene to Astrocytes in the Brain , 2001, The Journal of Neuroscience.

[200]  J. Poirier,et al.  β‐Amyloid Peptides Increase the Binding and Internalization of Apolipoprotein E to Hippocampal Neurons , 1998, Journal of neurochemistry.

[201]  S. D. Moore,et al.  Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology , 2005, Neurobiology of Disease.

[202]  Holly Soares,et al.  Cerebrospinal fluid β-amyloid1–42 and tau in control subjects at risk for Alzheimer’s disease: The effect of APOE ε4 allele , 2004, Biological Psychiatry.

[203]  R. Mahley,et al.  Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[204]  T. Wisniewski,et al.  Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. , 1995, The Biochemical journal.

[205]  B. Chromy,et al.  Amyloid-β peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release , 1998, Brain Research.

[206]  R. Mayeux.  Apolipoprotein E, Alzheimer disease, and African Americans. , 2003, Archives of neurology.

[207]  Christian Haass,et al.  The two faces of protein misfolding: gain‐ and loss‐of‐function in neurodegenerative diseases , 2008, The EMBO journal.

[208]  B. Hyman,et al.  The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor Published, JLR Papers in Press, May 1, 2005. DOI 10.1194/jlr.M500114-JLR200 , 2005, Journal of Lipid Research.

[209]  E Brisch,et al.  The Inhibitory Effect of Apolipoprotein E4 on Neurite Outgrowth Is Associated with Microtubule Depolymerization (*) , 1995, The Journal of Biological Chemistry.

[210]  J. Mazziotta,et al.  Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[211]  B. Hyman,et al.  Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[212]  R. E. Pitas,et al.  Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. , 1987, The Journal of biological chemistry.

[213]  L. J. Eldik,et al.  A dual role for apolipoprotein E in neuroinflammation , 2007, Journal of Molecular Neuroscience.

[214]  A. Fagan,et al.  Unique Lipoproteins Secreted by Primary Astrocytes From Wild Type, apoE (−/−), and Human apoE Transgenic Mice* , 1999, The Journal of Biological Chemistry.

[215]  A. Kurz,et al.  Apolipoprotein E epsilon 4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease , 1996, Neurology.

[216]  B. Hyman,et al.  Apolipoprotein E modulates γ‐secretase cleavage of the amyloid precursor protein , 2004, Journal of neurochemistry.

[217]  B. Strooper,et al.  Presenilin clinical mutations can affect γ‐secretase activity by different mechanisms , 2006, Journal of neurochemistry.

[218]  K. Ikeda,et al.  Neuronal localization of a novel mosaic apolipoprotein E receptor, LR11, in rat and human brain , 1999, Brain Research.

[219]  B. Hyman,et al.  Lack of allelic imbalance in APOE ϵ3/4 brain mRNA expression in Alzheimer's disease , 1999, Neuroscience Letters.

[220]  R. Demattos,et al.  A Test of the Cytosolic Apolipoprotein E Hypothesis Fails to Detect the Escape of Apolipoprotein E from the Endocytic Pathway into the Cytosol and Shows that Direct Expression of Apolipoprotein E in the Cytosol is Cytotoxic , 1999, The Journal of Neuroscience.

[221]  R. Demattos,et al.  A Minimally Lipidated Form of Cell-derived Apolipoprotein E Exhibits Isoform-specific Stimulation of Neurite Outgrowth in the Absence of Exogenous Lipids or Lipoproteins* , 1998, The Journal of Biological Chemistry.

[222]  D. Holtzman,et al.  Human Apolipoprotein E4 Alters the Amyloid-β 40:42 Ratio and Promotes the Formation of Cerebral Amyloid Angiopathy in an Amyloid Precursor Protein Transgenic Model , 2005, The Journal of Neuroscience.

[223]  Giovanni B. Frisoni,et al.  Gene dose of the ε4 allele of apolipoprotein E and disease progression in sporadic late‐onset alzheimer's disease , 1995 .

[224]  E. Otomo,et al.  Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease , 1991, Brain Research.

[225]  G. Frisoni,et al.  Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease. , 1995, Annals of neurology.

[226]  Y. Matsuoka,et al.  F-Spondin Interaction with the Apolipoprotein E Receptor ApoEr2 Affects Processing of Amyloid Precursor Protein , 2005, Molecular and Cellular Biology.

[227]  R. Mahley,et al.  Apolipoprotein E: far more than a lipid transport protein. , 2000, Annual review of genomics and human genetics.

[228]  K. Fukuchi,et al.  Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice , 2006, Neurobiology of Aging.

[229]  K. Lunetta,et al.  The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease , 2007, Nature Genetics.

[230]  Christopher Schatschneider,et al.  Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. , 2005, Archives of neurology.

[231]  K. Weisgraber,et al.  Effect of Domain Interaction on Apolipoprotein E Levels in Mouse Brain , 2005, The Journal of Neuroscience.

[232]  S. Tsuji,et al.  Aβ1–40 but not Aβ1–42 levels in cortex correlate with apolipoprotein E ϵ4 allele dosage in sporadic Alzheimer's disease , 1997, Brain Research.

[233]  Thomas Arendt,et al.  Plastic Neuronal Remodeling Is Impaired in Patients with Alzheimer’s Disease Carrying Apolipoprotein ε4 Allele , 1997, The Journal of Neuroscience.

[234]  D. Bennett,et al.  Sex-dependent association of a common low-density lipoprotein receptor polymorphism with RNA splicing efficiency in the brain and Alzheimer's disease. , 2007, Human molecular genetics.

[235]  D. Michaelson,et al.  A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[236]  I. McKeith,et al.  Effects of apolipoprotein E genotype on cortical neuropathology in senile dementia of the Lewy body and Alzheimer's disease. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[237]  J. Lazo,et al.  Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. , 2001, Biochemistry.

[238]  S. Fujita,et al.  Independent effects of APOE on cholesterol metabolism and brain Abeta levels in an Alzheimer disease mouse model. , 2004, Human molecular genetics.

[239]  C. Sensen,et al.  Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency , 1999, Nature Genetics.

[240]  Steven D. Edland,et al.  Accelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease , 1998, Neurology.

[241]  D. Mann,et al.  Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. , 1997, Neuroscience letters.

[242]  F. Liu,et al.  Human APOE Isoform-Dependent Effects on Brain β-Amyloid Levels in PDAPP Transgenic Mice , 2009, The Journal of Neuroscience.

[243]  J. Ma,et al.  Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides. , 1996, Neurobiology of aging.

[244]  G. Getz,et al.  Isoform-specific binding of apolipoprotein E to beta-amyloid. , 1994, The Journal of biological chemistry.

[245]  D. Quartermain,et al.  Blocking the apolipoprotein E/amyloid-β interaction as a potential therapeutic approach for Alzheimer's disease , 2006, Proceedings of the National Academy of Sciences.

[246]  S. Wilton,et al.  Apolipoprotein E and Alzheimer's disease , 1995 .

[247]  R. Mahley,et al.  Detrimental effects of apolipoprotein E4: potential therapeutic targets in Alzheimer's disease. , 2007, Current Alzheimer research.

[248]  G. Alexander,et al.  Correlations between apolipoprotein E ε4 gene dose and brain-imaging measurements of regional hypometabolism , 2005 .

[249]  C. Finch,et al.  Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. , 1995, Brain research. Molecular brain research.

[250]  B. Hyman,et al.  Lack of allelic imbalance in APOE epsilon3/4 brain mRNA expression in Alzheimer's disease. , 1999, Neuroscience letters.

[251]  M. Pericak-Vance,et al.  Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[252]  S. Blacklow.  Versatility in ligand recognition by LDL receptor family proteins: advances and frontiers. , 2007, Current opinion in structural biology.

[253]  D. Holtzman,et al.  Deletion of Abca1 Increases Aβ Deposition in the PDAPP Transgenic Mouse Model of Alzheimer Disease* , 2005, Journal of Biological Chemistry.

[254]  H. Soininen,et al.  Genetic study evaluating LDLR polymorphisms and Alzheimer's disease , 2008, Neurobiology of Aging.

[255]  L. Wahlund,et al.  Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein , 1997, Neuroscience Letters.

[256]  M. Owen,et al.  Allelic expression of APOE in human brain: effects of epsilon status and promoter haplotypes. , 2004, Human molecular genetics.

[257]  G. Alexander,et al.  Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. , 2002, The American journal of psychiatry.

[258]  A. Delacourte,et al.  Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease , 1996, Neuroscience Letters.

[259]  S. Paul,et al.  Neuroinflammation and Alzheimer's disease: critical roles for cytokine/Abeta-induced glial activation, NF-kappaB, and apolipoprotein E. , 2000, Neurobiology of aging.

[260]  J. Gilbert,et al.  Human Apolipoprotein E2, E3, and E4 Isoform-Specific Transgenic Mice: Human-like Pattern of GlialandNeuronal Immunoreactivity in Central Nervous System Not Observed in Wild-Type Mice , 1996, Neurobiology of Disease.

[261]  D. Holtzman,et al.  Amyloid beta40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. , 2001, Journal of Alzheimer's disease : JAD.

[262]  D. Schmechel,et al.  Marked regional differences of brain human apolipoprotein e expression in targeted replacement mice , 2004, Neuroscience.

[263]  F. Pfrieger,et al.  Cholesterol homeostasis and function in neurons of the central nervous system , 2003, Cellular and Molecular Life Sciences CMLS.

[264]  M. Gearing,et al.  Aβ‐peptide length aid apolipoprotein E genotype in Alzheimer's disease , 1996 .

[265]  J. Hardy,et al.  Distortion of allelic expression of apolipoprotein E in Alzheimer's disease. , 1997, Human molecular genetics.

[266]  D. Selkoe,et al.  Co-expression of beta-amyloid precursor protein (betaAPP) and apolipoprotein E in cell culture: analysis of betaAPP processing. , 1995, Neurobiology of disease.

[267]  S. Paul,et al.  Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides , 2004, Nature Medicine.

[268]  B. Hyman,et al.  Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions , 1993, Neuron.